Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Witt

Showing results (131-140 of 242) with videos related to

Pageof 25
Sort By:
Journal of Neuro-Oncology|October 7, 2020
Response to trametinib treatment in progressive pediatric low-grade glioma patientsFlorian Selt, Cornelis M van Tilburg, Brigitte Bison, et al.
NPJ Precision Oncology|June 17, 2026
Integration and validation of complementary ex vivo assays for functional precision oncologyAnna Loboda, Jasmina Paluncic, Micaela Freitas, et al.
Molecular Cancer Therapeutics|May 27, 2020
A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in <i>BRAF</i>-Driven Pediatric Low-Grade Glioma CellsDiren Usta, Romain Sigaud, Juliane L Buhl, et al.
Acta Neuropathologica|August 25, 2011
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor VorinostatTill Milde, Susanne Kleber, Andrey Korshunov, et al.
Acta Neuropathologica|March 11, 2015
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markersAndrey Korshunov, Marina Ryzhova, Volker Hovestadt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastomaElke Pfaff, Marc Remke, Dominik Sturm, et al.
BMC Cancer|June 7, 2020
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignanciesCornelis M van Tilburg, Ruth Witt, Melanie Heiss, et al.
Lancet (London, England)|November 20, 2012
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trialDavid Neal Franz, Elena Belousova, Steven Sparagana, et al.
Klinische Padiatrie|February 21, 2020
Correction: SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade GliomaAstrid K Gnekow, Daniela Kandels, Cornelis van Tilburg, et al.
Klinische Padiatrie|May 21, 2019
SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade GliomaAstrid K Gnekow, Daniela Kandels, Cornelis van Tilburg, et al.
Pageof 25

Showing results (131-140 of 242) with videos related to

Sort By:
Pageof 25
Journal of Neuro-Oncology|October 7, 2020
Response to trametinib treatment in progressive pediatric low-grade glioma patientsFlorian Selt, Cornelis M van Tilburg, Brigitte Bison, et al.
NPJ Precision Oncology|June 17, 2026
Integration and validation of complementary ex vivo assays for functional precision oncologyAnna Loboda, Jasmina Paluncic, Micaela Freitas, et al.
Molecular Cancer Therapeutics|May 27, 2020
A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in <i>BRAF</i>-Driven Pediatric Low-Grade Glioma CellsDiren Usta, Romain Sigaud, Juliane L Buhl, et al.
Acta Neuropathologica|August 25, 2011
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor VorinostatTill Milde, Susanne Kleber, Andrey Korshunov, et al.
Acta Neuropathologica|March 11, 2015
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markersAndrey Korshunov, Marina Ryzhova, Volker Hovestadt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastomaElke Pfaff, Marc Remke, Dominik Sturm, et al.
BMC Cancer|June 7, 2020
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignanciesCornelis M van Tilburg, Ruth Witt, Melanie Heiss, et al.
Lancet (London, England)|November 20, 2012
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trialDavid Neal Franz, Elena Belousova, Steven Sparagana, et al.
Klinische Padiatrie|February 21, 2020
Correction: SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade GliomaAstrid K Gnekow, Daniela Kandels, Cornelis van Tilburg, et al.
Klinische Padiatrie|May 21, 2019
SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade GliomaAstrid K Gnekow, Daniela Kandels, Cornelis van Tilburg, et al.
Pageof 25